Lynda Charters

Varun Chaudhary, MD, FRCSC, addressed the big questions in treating patients with retinal vascular diseases: who will and will not respond to treatment and what clues are predictive on imaging, at the Retina 2024 meeting in Maui.

In his presentation, Eichenbaum defined gene therapy and described its use in common retinal disease.

The data indicated that patients with Alzheimer’s disease who were treated with acetylcholinesterase inhibitors had a slightly lower hazard of developing AMD compared with untreated patients.

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.

Gather, participate, learn, socialize

The 24th annual Retina Fellows Forum will take place on January 25 and 26, 2024 in Chicago at the Westin Chicago River North hotel.

The kidney and eye are structurally and functionally similar, and the diseases of the organs may present similarly and via common pathways.

The predictive factors were the previous number of anti-vascular endothelial growth factor and the photometry laser flare-cell (LFCP) value.

Austrian investigators advise establishing an interdisciplinary setting, ie, rheumatologic–ophthalmologic, to improve management of patients with rheumatic diseases.

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD.

The investigators wanted to determine if subclinical changes in the blood–aqueous barrier and the retinal physiology developed after anti-VEGF treatments with aflibercept, brolucizumab, and or faricimab .

Researchers conducted a large nationwide, population-based, retrospective cohort study to determine if there is an association between COVID-19 infection and vaccination with neuro-ophthalmic adverse events.

This retrospective, cross-sectional study identified all inpatient diagnosed with syphilitic uveitis in the US between 2010 and 2019.

Moving toward eliminating drug and chemical safety testing in animals

This was a 52-week, double-masked, phase 3 randomized clinical trial in which treatment-naive adults and adults who had previously received anti-VEGF therapy for DME were included.

The investigators use mindfulness-based cognitive therapy (MBCT) on patients who have never previously practiced the technique, with the aim of possibly re-training their brains to remove their static-type images.

At first glance, these patients can appear to have normal or near-normal visual acuity levels. However, in reality, many have perceptual visual deficits, which are not typically tested during a standard ophthalmology office evaluation.

An anchored matching-adjusted indirect comparison may aid therapeutic decision-making.

NYU Langone Health performs landmark procedure called “major paradigm shift for potential vision therapies”

Patients treated every other month with the drug also showed a similar decrease in the rate of GA progression compared with sham treatment.

They believe that these phenotypic differences in GA should be considered in different ethnicities because they may have implications in research and in interventions to slow progression of GA.

Researchers found that spontaneous macular hole closure and surgical treatment seem to be associated with comparable rates of closure and visual outcomes.

The purpose of this investigation was 2-fold: to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA.

OCT and OCTA imaging were especially valuable in this patient population because the images extended the current definition of sickle cell retinopathy.

Investigators have proposed a new algorithm, TWO-ROP, which they describe as “a new and simple screening protocol with a two-tiered impatient and outpatient approach.”

Researchers underscored the importance of ocular examinations in patients with primary vasculitis, defined as without an apparent cause.

Identifying and surmounting gender barriers in ophthalmology.

The American Academy of Ophthalmology (AAO) 2023 annual meeting is returning home to San Francisco on Friday November 3 through Monday November 6.

The use of silicone-free syringes advised with these drops.